Literature DB >> 17602941

ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis.

Javier D Finkielman1, Augustine S Lee, Amber M Hummel, Margaret A Viss, Gregory L Jacob, Henry A Homburger, Tobias Peikert, Gary S Hoffman, Peter A Merkel, Robert Spiera, E William St Clair, John C Davis, W Joseph McCune, Andrea K Tibbs, Steven R Ytterberg, John H Stone, Ulrich Specks.   

Abstract

BACKGROUND: The pathogenic significance of antineutrophilic cytoplasmic antibodies (ANCA) in Wegener's granulomatosis is controversial. Their presence is influenced by the extent, severity, and activity of the disease at the time of sampling. The objective of this study was to determine the frequency of ANCA in patients with active Wegener's granulomatosis and to assess the influence of disease severity on test results.
METHODS: Baseline serum samples from the 180 participants in a multicentric prospective trial were tested for ANCA by indirect immunofluorescence, direct enzyme-linked immunosorbent assay (ELISA), and capture ELISA. Disease activity was measured using the Birmingham Vasculitis Activity Score for Wegener's granulomatosis. All patients had active disease at enrollment. Patients were categorized as having severe (n=128) or limited (n=52) Wegener's granulomatosis.
RESULTS: When all ANCA detection methods were combined, 166 patients (92%) were ANCA positive, including 96% with severe disease and 83% with limited disease.
CONCLUSION: ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis, but approximately 1 of 5 patients with active limited disease are ANCA negative. Immunofluorescence and both direct and capture ELISAs are required for optimal detection, suggesting that ANCA are not recognized equally well by all testing methods.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602941     DOI: 10.1016/j.amjmed.2006.08.016

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  78 in total

1.  Systemic vasculitis: a dual diagnosis?

Authors:  Eliza Gil; Pamela Lutalo; David D'Cruz
Journal:  BMJ Case Rep       Date:  2011-12-02

2.  IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.

Authors:  James M Kelley; Paul A Monach; Chuanyi Ji; Yebin Zhou; Jianming Wu; Sumiaki Tanaka; Alfred D Mahr; Sharleen Johnson; Carol McAlear; David Cuthbertson; Simon Carette; John C Davis; Paul F Dellaripa; Gary S Hoffman; Nader Khalidi; Carol A Langford; Phillip Seo; E William St Clair; Ulrich Specks; John H Stone; Robert F Spiera; Steven R Ytterberg; Peter A Merkel; Jeffrey C Edberg; Robert P Kimberly
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-06       Impact factor: 11.205

3.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

Review 4.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

5.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

6.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Authors:  Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks
Journal:  Ann Rheum Dis       Date:  2015-11-30       Impact factor: 19.103

Review 7.  Granulomatosis with polyangiitis in childhood.

Authors:  Marinka Twilt; Susanne Benseler; David Cabral
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 8.  Wegener's granulomatosis: the current view.

Authors:  Frank Moosig; Peter Lamprecht; Wolfgang L Gross
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 9.  Biomarkers in ANCA-associated vasculitis.

Authors:  Lindsay Lally; Robert F Spiera
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

Review 10.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.